Lidaltrin (Quinapril Hydrochloride)

Quinapril is converted in the body to quinaprilat, which blocks the angiotensin‑converting enzyme. This inhibition stops the formation of angiotensin II, a potent vasoconstrictor, leading to relaxed blood vessels, reduced aldosterone release, and lower blood pressure, while also decreasing the strain on the heart.

The appropriate dose of quinapril is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and renal function. Dosage adjustments may be required for elderly patients or those with kidney impairment, and the prescriber will provide specific instructions.

Safety of quinapril in pregnancy has not been established, and ACE inhibitors are generally avoided because of potential fetal toxicity, especially in the second and third trimesters. Breastfeeding mothers should consult their healthcare provider, as quinapril may be excreted in breast milk.

To place an order, submit an enquiry on the Lidaltrin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Quinapril shares the core mechanism of ACE inhibition with other agents in its class, offering comparable blood‑pressure‑lowering efficacy. Some clinicians prefer quinapril for its once‑daily dosing and a relatively lower incidence of cough compared with certain alternatives, but individual response and tolerability vary.

Lidaltrin should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Lidaltrin is taken orally, usually once daily or as directed by the prescriber. It should be swallowed whole with a full glass of water, and can be taken with or without food. Patients should follow the dosing schedule provided by their healthcare professional.

The most serious adverse reactions include angioedema (swelling of the face, lips, tongue, or throat), severe hypotension, acute kidney injury, and hyperkalaemia. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, sudden dizziness, or a rapid decline in kidney function.

Quinapril is contraindicated in individuals with a known hypersensitivity to quinapril or any ACE inhibitor, a history of angioedema related to ACE‑inhibitor therapy, and in patients with hereditary or idiopathic angioedema. Caution is also advised for those with severe renal impairment or bilateral renal artery stenosis.